- Home
- NVCR vs ELVN Comparison
NVCR vs ELVN Comparison
Compare NVCR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- ELVN
- Stock Information
- Founded
- NVCR 2000
- ELVN 2016
- Country
- NVCR Switzerland
- ELVN United States
- Employees
- NVCR N/A
- ELVN N/A
- Industry
- NVCR Medical/Dental Instruments
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- ELVN Health Care
- Exchange
- NVCR Nasdaq
- ELVN Nasdaq
- Market Cap
- NVCR 1.4B
- ELVN 1.2B
- IPO Year
- NVCR 2015
- ELVN 2020
- Fundamental
- Price
- NVCR $13.77
- ELVN $20.64
- Analyst Decision
- NVCR Buy
- ELVN Strong Buy
- Analyst Count
- NVCR 7
- ELVN 5
- Target Price
- NVCR $28.79
- ELVN $41.20
- AVG Volume (30 Days)
- NVCR 1.6M
- ELVN 404.5K
- Earning Date
- NVCR 10-30-2025
- ELVN 11-12-2025
- Dividend Yield
- NVCR N/A
- ELVN N/A
- EPS Growth
- NVCR N/A
- ELVN N/A
- EPS
- NVCR N/A
- ELVN N/A
- Revenue
- NVCR $630,160,000.00
- ELVN N/A
- Revenue This Year
- NVCR $6.68
- ELVN N/A
- Revenue Next Year
- NVCR $7.01
- ELVN $20.05
- P/E Ratio
- NVCR N/A
- ELVN N/A
- Revenue Growth
- NVCR 14.58
- ELVN N/A
- 52 Week Low
- NVCR $10.87
- ELVN $13.30
- 52 Week High
- NVCR $34.13
- ELVN $29.79
- Technical
- Relative Strength Index (RSI)
- NVCR 51.39
- ELVN 50.60
- Support Level
- NVCR $13.57
- ELVN $20.10
- Resistance Level
- NVCR $14.58
- ELVN $22.36
- Average True Range (ATR)
- NVCR 0.64
- ELVN 0.94
- MACD
- NVCR -0.05
- ELVN -0.05
- Stochastic Oscillator
- NVCR 49.59
- ELVN 28.03
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.